文献速递免疫规划卫生政策与健康促进

美国人群医疗状况背景发病率用于COVID-19疫苗安全性评估

U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines.
PubMed 文献 · Vaccine · 2021-05-14

为支持COVID-19疫苗安全性监测,美国FDA和CDC专家列出22种潜在特别关注不良事件(AESI),并从已发表统计和PubMed文献综述中获取美国背景发病率,按年龄、性别和种族/民族分层,为评估接种后时间关联事件提供参照。

要点

  • 背景发病率是疫苗安全性监测中区分偶合事件与疫苗相关事件的关键参照。
  • FDA和CDC专家确定了22种神经系统、自身免疫和心血管等AESI。
  • 背景率来自已发表统计和PubMed文献综述,部分按年龄、性别、种族分层。

核心结论

  • 本综述提供了可能作为COVID-19疫苗安全性监测AESI的医疗状况的美国背景发病率估计。
  • 背景发病率知识有助于将接种后时间关联事件与单纯偶然预期事件进行对比评估。

研究设计与样本

  • 综述类研究:由FDA和CDC主题专家编制22种AESI清单,并从已发表统计和PubMed文献综述中获取美国背景发病率。

主要发现

  • AESI清单包括神经、自身免疫和心血管疾病等22种潜在不良事件。
  • 背景发病率数据按总体及年龄、性别、种族/民族(当可获取时)分层。

临床怎么用

  • 在COVID-19疫苗安全性监测中,可将观察到的事件率与本文提供的背景发病率比较,辅助判断事件是否超出偶然预期。

局限性

  • 背景发病率来源于已发表统计和文献综述,而非原始数据统一分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Coronavirus Disease 2019 (COVID-19) pandemic has had a devastating impact on global health, and has resulted in an unprecedented, international collaborative effort to develop vaccines to control the outbreak, protect human lives, and avoid further social and economic disruption. Mass vaccination campaigns are underway in multiple countries and are expected worldwide once more vaccine becomes available. Some early candidate vaccines use novel platforms, such as mRNA encapsulated in lipid nanoparticles, and relatively new platforms, such as replication-deficient viral vectors. While these new vaccine platforms hold promise, limited safety data in humans are available. Serious health outcomes linked to vaccinations are rare, and some outcomes may occur incidentally in the vaccinated population. Knowledge of background incidence rates of these medical conditions is a critical component of vaccine safety monitoring to aid in the assessment of adverse events temporally associated with vaccination and to put these events into context with what would be expected due to chance alone. A list of 22 potential adverse events of special interest (AESI), including neurologic, autoimmune, and cardiovascular disorders, was compiled by subject matter experts at the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention. The most recently available U.S. background rates for these medical conditions, overall and by age, sex, and race/ethnicity (when available), were sourced from reported statistics (data published by medical panels/ associations or federal government reports), and literature reviews in PubMed. This review provides estimates of background incidence rates for medical conditions that may be monitored or studied as AESI during safety surveillance and research for COVID-19 vaccines and other new vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gubernot D, Jazwa A, Niu M, et al. U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine. 2021. PMID: 34088506. doi:10.1016/j.vaccine.2021.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。